Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitamin B 12 factor IIIm is a synthetic analog of vitamin B12 (cobalamin) in which the lower axial ligand (the base attached to the cobalt atom) is a 5-methoxybenzimidazole group instead of the more common dimethylbenzimidazole found in naturally occurring cobalamins. It is also known as cyano-5-methoxybenzimidazolylcobamide. This compound belongs to the broader class of cobalamins and shares their core structure and biological relevance as cofactors in enzymatic reactions involving methyl group transfers and rearrangements. However, Vitamin B 12 factor IIIm itself is considered experimental and has not been approved for clinical use or supplementation[1][3]. Its mechanism of action would be expected to parallel that of other cobalamins—serving as a cofactor for enzymes such as methionine synthase and methylmalonyl-CoA mutase—but its altered lower ligand may affect its binding properties or bioavailability compared to standard forms like cyanocobalamin or methylcobalamin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitamin B 12 factor IIIm.